Mark R. BamforthFounder, President & CEO, Brammer Biopharmaceuticals, LLC
Mark Bamforth is currently establishing a cell and gene therapy contract manufacturing organization (CMO), Brammer Biopharmaceuticals.
In 2010, Bamforth founded and led Gallus BioPharmaceuticals, a premier CMO delivering clinical and commercial biopharmaceuticals to pharma and biotech companies worldwide. Since the acquisition of a St. Louis world-class facility in 2011, with an experienced operations team and a supply agreement for two leading commercial monoclonal antibodies for Janssen, Gallus tripled through organic growth and a 2013 merger with another CMO, Laureate Biopharma. With Gallus’ PE investors, Bamforth managed the sale of Gallus to DPx Holdings B.V. (aka Patheon) in Sept. 2014 and supported the integration.
Bamforth has 22 years of previous experience in the UK and USA running a diverse, global manufacturing operation and a pharmaceutical CMO business for Genzyme Corp. He began his career as a petroleum engineer exploring for North Sea oil, then as a chemical engineer in the whisky industry.
Bamforth serves on the MassBio Board and is a Saltire Foundation founding-trustee, enabling young Scottish entrepreneurs to expand their business knowledge through education and internships with high growth USA companies. He has a BS in Chemical Engineering from Strathclyde University and an MBA from Henley Management College. He lives in Cambridge, MA with his wife and two children.